Latest news with #THB2.66
Yahoo
2 days ago
- Business
- Yahoo
Asian Penny Stocks With Market Caps At Least US$200M
As global markets navigate through volatility and trade tensions, Asian markets are under the spotlight for their resilience and growth potential. Penny stocks, a term that may seem outdated yet remains relevant, represent an intriguing investment area within these dynamic economies. By focusing on financial strength and long-term potential, this article explores several penny stocks in Asia that could offer surprising value to investors seeking opportunities in smaller or newer companies. Name Share Price Market Cap Financial Health Rating Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC) THB1.79 THB751.8M ★★★★★★ Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.425 SGD172.25M ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.179 SGD35.66M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.09 SGD8.23B ★★★★★☆ Ever Sunshine Services Group (SEHK:1995) HK$1.93 HK$3.34B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.50 HK$51.52B ★★★★★★ Lever Style (SEHK:1346) HK$1.19 HK$750.83M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.27 HK$2.12B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.95 HK$1.62B ★★★★★★ Click here to see the full list of 1,157 stocks from our Asian Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Huanxi Media Group Limited is an investment holding company involved in the media and entertainment sectors in China and Hong Kong, with a market cap of HK$1.68 billion. Operations: The company generates revenue from its investment in film and TV programmes rights, amounting to HK$34.18 million. Market Cap: HK$1.68B Huanxi Media Group, operating in the media and entertainment sectors in China and Hong Kong, has a market cap of HK$1.68 billion but reported a significant drop in revenue to HK$34.18 million for 2024, compared to HK$1.33 billion the previous year. The company is unprofitable with a net loss of HK$260.82 million for 2024, attributed partly to delayed film releases expected to debut in 2025. Despite having more cash than debt and covering both short- and long-term liabilities with assets totaling HK$1.2 billion, it faces challenges with less than a year of cash runway if current free cash flow trends continue. Navigate through the intricacies of Huanxi Media Group with our comprehensive balance sheet health report here. Gain insights into Huanxi Media Group's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company involved in the research, development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in China, with a market cap of HK$8.69 billion. Operations: The company's revenue is derived from three main segments: Generic Medicine contributing CN¥1.10 billion, Medical Aesthetic Products generating CN¥744.22 million, and Innovative Medicine and Other Medicine adding CN¥109.67 million. Market Cap: HK$8.69B Sihuan Pharmaceutical Holdings Group, with a market cap of HK$8.69 billion, is navigating the challenges of unprofitability while leveraging its robust product pipeline in China's pharmaceutical and medical aesthetic sectors. Recent approvals for its PLLA and PCL fillers position it uniquely within the regenerative medical aesthetics market, potentially enhancing revenue streams as these products gain traction. Despite reporting a net loss of CN¥216.66 million for 2024, the company maintains strong short-term liquidity with assets exceeding liabilities and more cash than debt. The approval of Dapagliflozin Tablets further strengthens its diabetes treatment portfolio, offering potential growth avenues despite current financial setbacks. Click here to discover the nuances of Sihuan Pharmaceutical Holdings Group with our detailed analytical financial health report. Gain insights into Sihuan Pharmaceutical Holdings Group's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Tianjin Chase Sun Pharmaceutical Co., Ltd is involved in the research, development, production, and sale of pharmaceutical products both in China and internationally, with a market cap of CN¥11.42 billion. Operations: No specific revenue segments are reported for Tianjin Chase Sun Pharmaceutical Co., Ltd. Market Cap: CN¥11.42B Tianjin Chase Sun Pharmaceutical, with a market cap of CN¥11.42 billion, is experiencing significant challenges in earnings growth, having reported negative earnings growth over the past year. Despite this, the company maintains strong liquidity with short-term assets of CN¥6.1 billion exceeding both short and long-term liabilities. The management team and board are considered experienced with average tenures of 2.1 and 3.2 years respectively. Recent dividend affirmations indicate some level of shareholder returns, although the dividend yield remains low at 0.79%. The company's debt is well covered by operating cash flow and interest payments by EBIT, reflecting solid financial health amidst volatility in profit margins. Take a closer look at Tianjin Chase Sun PharmaceuticalLtd's potential here in our financial health report. Review our growth performance report to gain insights into Tianjin Chase Sun PharmaceuticalLtd's future. Access the full spectrum of 1,157 Asian Penny Stocks by clicking on this link. Looking For Alternative Opportunities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1003 SEHK:460 and SZSE:300026. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Asian Penny Stocks To Consider In May 2025
As global markets face volatility and economic uncertainties, the Asian stock market continues to capture attention with its unique dynamics and opportunities. Penny stocks, often associated with smaller or newer companies, remain a relevant investment area despite being considered somewhat outdated. By focusing on those with robust financials and growth potential, investors can uncover hidden gems that offer stability alongside promising prospects for growth. Name Share Price Market Cap Financial Health Rating Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.43 SGD174.27M ★★★★★☆ YKGI (Catalist:YK9) SGD0.096 SGD40.8M ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.179 SGD35.66M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.08 SGD8.19B ★★★★★☆ Ever Sunshine Services Group (SEHK:1995) HK$1.90 HK$3.28B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.53 HK$51.86B ★★★★★★ Lever Style (SEHK:1346) HK$1.17 HK$738.21M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.23 HK$2.05B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.94 HK$1.62B ★★★★★★ Click here to see the full list of 1,167 stocks from our Asian Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: EROAD Limited offers electronic on-board units and software as a service to the transport industry across New Zealand, the United States, and Australia, with a market cap of NZ$252.48 million. Operations: The company has not reported specific revenue segments. Market Cap: NZ$252.48M EROAD Limited, with a market cap of NZ$252.48 million, has shown promising financial performance by achieving profitability recently and reporting sales of NZ$194.4 million for the fiscal year ended March 31, 2025. The company's net income was NZ$1.4 million compared to a net loss the previous year, indicating improved margins. EROAD's debt management is commendable with a reduced debt to equity ratio from 69.8% to 8% over five years and satisfactory net debt levels at 3.8%. However, challenges remain with high share price volatility and an inexperienced board and management team impacting stability perceptions in the penny stock landscape. Unlock comprehensive insights into our analysis of EROAD stock in this financial health report. Review our growth performance report to gain insights into EROAD's future. Simply Wall St Financial Health Rating: ★★★★★★ Overview: China Ding Yi Feng Holdings Limited is a publicly owned investment manager with a market cap of HK$569.92 million. Operations: The company's revenue segment is Investment Holding, which reported a revenue of -HK$245.20 million. Market Cap: HK$569.92M Ding Yi Feng Holdings Group International, with a market cap of HK$569.92 million, is pre-revenue and reported substantial negative revenue of -HK$367.55 million for 2024. Despite its unprofitable status and high volatility compared to other Hong Kong stocks, the company maintains a debt-free position with short-term assets exceeding liabilities significantly. The seasoned board has an average tenure of 8.8 years, which may provide stability amid recent changes like auditor transitions announced in May 2025. While the stock's price remains volatile, sufficient cash reserves suggest operational continuity for over a year without additional funding needs. Click here and access our complete financial health analysis report to understand the dynamics of Ding Yi Feng Holdings Group International. Gain insights into Ding Yi Feng Holdings Group International's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Boustead Singapore Limited is an investment holding company that offers energy engineering, real estate, geospatial, and healthcare technology solutions across various regions worldwide with a market capitalization of SGD560.45 million. Operations: No specific revenue segments are reported for this company. Market Cap: SGD560.45M Boustead Singapore Limited, with a market cap of SGD560.45 million, recently reported full-year sales of SGD527.1 million and net income growth to SGD95.05 million, reflecting improved profit margins from 8.4% to 18%. The company shows financial robustness with cash exceeding total debt and high operating cash flow coverage of debt at 970.2%. Earnings have grown significantly by 48.1% over the past year, surpassing both its five-year average and industry growth rates. While trading below estimated fair value by 44.5%, the stock's dividend track record remains unstable despite strong short-term asset coverage over liabilities. Click here to discover the nuances of Boustead Singapore with our detailed analytical financial health report. Learn about Boustead Singapore's historical performance here. Explore the 1,167 names from our Asian Penny Stocks screener here. Want To Explore Some Alternatives? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NZSE:ERD SEHK:612 and SGX:F9D. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
